GeNeo

GeNeo predicts neoepitopes from somatic variants detected in high-throughput DNA and RNA sequencing to support personalized cancer vaccine design.

Key Features:

• Somatic Variant Calling and Filtering: Identifies somatic variants from high-throughput DNA and RNA sequencing and applies calling and filtering algorithms to detect mutations relevant to neoepitope prediction.
• Variant Validation: Provides mechanisms for validating identified somatic variants to confirm their presence and relevance in clinical tumor samples.
• Neoepitope Prediction and Filtering: Predicts potential neoepitopes from validated somatic variants and filters them using immunogenicity criteria to prioritize candidates.

Scientific Applications:

• Personalized cancer vaccine design: Enables identification and prioritization of tumor-specific neoepitopes for individualized cancer vaccine development.
• Precision oncology neoepitope discovery: Supports discovery of immunogenic neoepitopes from patient-derived tumor samples to inform targeted immunotherapies.

Methodology:

Inputs are high-throughput DNA and RNA sequencing data; somatic variants are called and filtered using computational algorithms; identified variants undergo validation; validated variants are used to predict and filter neoepitopes based on immunogenicity criteria.